Zydus Cadila gets USFDA nod for Tizanidine tablets 

Cadila Healthcare today said its group firm Zydus Cadila has received final approval from the US health regulator for its generic version of Tizanidine tablets used for treatment of muscle spasms.

Published: 13th March 2018 01:47 PM  |   Last Updated: 13th March 2018 01:47 PM   |  A+A-

Image for representational purpose only.

By PTI

NEW DELHI: Cadila Healthcare today said its group firm Zydus Cadila has received final approval from the US health regulator for its generic version of Tizanidine tablets used for treatment of muscle spasms.

The approval by the US Food and Drug Adminstration (USFDA) is for multiple strengths of 2 mg and 4 mg, the company said in a BSE filing.

The tablets will be manufactured at the group's formulations manufacturing facility at SEZ, Ahmedabad, the company added.

Tizanidine tablets are used to treat muscle spasms caused by certain conditions such as multiple sclerosis, spinal cord injury, it said.

The group has more than 180 approvals with over 320 abbreviated new drug approvals (ANDAs) filed since 2003-04, the company said.

Stay up to date on all the latest Business news with The New Indian Express App. Download now
(Get the news that matters from New Indian Express on WhatsApp. Click this link and hit 'Click to Subscribe'. Follow the instructions after that.)

Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.

flipboard facebook twitter whatsapp